GREPPI, MARCO
 Distribuzione geografica
Continente #
EU - Europa 3.288
AS - Asia 231
NA - Nord America 41
SA - Sud America 33
AF - Africa 8
Totale 3.601
Nazione #
IT - Italia 3.278
SG - Singapore 84
CN - Cina 74
VN - Vietnam 58
US - Stati Uniti d'America 36
BR - Brasile 25
HK - Hong Kong 8
MX - Messico 5
AR - Argentina 3
IQ - Iraq 3
BD - Bangladesh 2
BG - Bulgaria 2
CL - Cile 2
ES - Italia 2
MA - Marocco 2
CH - Svizzera 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
ET - Etiopia 1
GB - Regno Unito 1
ID - Indonesia 1
MD - Moldavia 1
PE - Perù 1
PY - Paraguay 1
RU - Federazione Russa 1
SE - Svezia 1
SO - Somalia 1
TN - Tunisia 1
TR - Turchia 1
UA - Ucraina 1
ZA - Sudafrica 1
Totale 3.601
Città #
Genoa 1.465
Genova 1.130
Vado Ligure 338
Rapallo 299
Milan 23
Singapore 23
Ho Chi Minh City 21
Beijing 20
Hanoi 17
Ashburn 16
Bordighera 12
Hong Kong 8
Los Angeles 6
Haiphong 5
Chieti 3
Da Nang 3
Rome 3
San Jose 3
Baghdad 2
Barcelona 2
Maringá 2
Mexico City 2
New York 2
Tianjin 2
Abadia de Goiás 1
Addis Ababa 1
Agadir 1
Algiers 1
Ankara 1
Arequipa 1
Bahía Blanca 1
Balsas 1
Bandung 1
Caldas Novas 1
Can Tho 1
Casablanca 1
Chicago 1
Chisinau 1
Colina 1
Curitiba 1
Curvelo 1
Erbil 1
Estación Colina 1
Giza 1
Goiânia 1
Hargeisa 1
Hercules 1
Hermosillo 1
Hải Dương 1
Ibach 1
Itapevi 1
Itatiba 1
Izhevsk 1
Jackson 1
Johannesburg 1
Katueté 1
Kostandovo 1
Kyiv 1
La Rioja 1
Laguna 1
Menzel Temime 1
Ninh Bình 1
Orem 1
Osasco 1
Palotina 1
Paracatu 1
Phoenix 1
Phúc Yên 1
Poplar 1
Portoviejo 1
Pouso Alegre 1
Querétaro City 1
Quảng Ngãi 1
Ribeirão das Neves 1
Salta 1
Santa Clara 1
Sobral 1
Sofia 1
Sorocaba 1
Stockholm 1
Sumaré 1
São José do Rio Preto 1
São Paulo 1
Topeka 1
Torres 1
Torreón 1
Tupandi 1
Vespasiano 1
Vilhena 1
Vinh 1
Zhoukou 1
Zhuhai 1
Ürümqi 1
Totale 3.476
Nome #
New miRNA signature heralds human NK cell subsets at different maturation steps: Involvement of miR-146a-5p in the regulation of KIR expression 203
Different features of tumor-associated NK cells in patients with low-grade or high-grade peritoneal carcinomatosis 197
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization 195
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization 157
Harnessing NK Cells for Cancer Treatment 155
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 150
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells 139
Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes 129
PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua 128
New miRNA signature heralds human NK cell subsets at different maturation steps: involvement of miR- 146a-5p in the regulation of KIR expression 120
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization 117
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 114
NK Cell-Based Immunotherapy in Colorectal Cancer 110
Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer 110
Role of the main non HLA-specific activating NK receptors in pancreatic, colorectal and gastric tumors surveillance 109
New Insights into Endometrial Cancer 108
miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy 108
Harnessing Immune Response in Acute Myeloid Leukemia 106
Expression, role and regulation of NK cell immune checkpoints (PD-1, KIRs, NKG2A) in Ovarian Cancer 98
Histopathological And Immunohistochemical Prognostic Factors In High-Grade Non-Endometrioid Carcinomas Of The Endometrium (Hg-Necs). Is It Possible To Identify Sub-Groups At Increased Risk? 91
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances 88
PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua 84
The PD-1 immune checkpoint on human NK cells in normal and pathological condition 82
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer 81
A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans 78
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art 77
Identification of a novel cord blood NK cell subpopulation expressing functional programmed death receptor-1 66
null 66
The PD-1 immune checkpoint on human NK cells in normal and pathological condition 60
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers 60
A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans 57
Relevant role for PD-1 immune checkpoint expressed on NK cells derived from ovarian cancer patients 55
Case Report: A Peculiar Case of Inflammatory Colitis After SARS-CoV-2 Infection 54
Relevant role for PD-1 immune checkpoint expressed on NK cells derived from ovarian cancer patients 42
PD-1+ NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade 37
Colorectal cancer-infiltrating NK cell landscape analysis unravels tissue-resident PD-1+ NK cells in microsatellite instability tumors 29
The Role of the Androgen Receptor (AR) in Endometrial Cancer Aggressiveness: Correlation with Other Prognostic Markers and Therapeutic Implications. A Retrospective Observational Study 27
Tumor-Infiltrating Natural Killer Cells 21
Case report: Non-invasive cyto-salivary sampling and biomarker detection via ELISA versus histopathology for diagnosing oral potentially malignant disorders - Insights from a case-control study 9
Totale 3.717
Categoria #
all - tutte 13.415
article - articoli 10.888
book - libri 0
conference - conferenze 1.726
curatela - curatele 0
other - altro 463
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.492


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021243 0 0 0 0 0 71 3 15 30 52 37 35
2021/2022298 9 9 17 23 28 26 16 61 38 27 17 27
2022/2023359 35 32 6 28 57 44 2 28 70 6 42 9
2023/2024349 13 36 9 43 22 35 33 58 16 21 26 37
2024/2025970 36 55 37 74 92 90 104 170 34 67 98 113
2025/2026832 190 48 125 167 225 77 0 0 0 0 0 0
Totale 3.717